Literature DB >> 33069873

Dietary fat, bile acid metabolism and colorectal cancer.

Soeren Ocvirk1, Stephen J D O'Keefe2.   

Abstract

Colorectal cancer (CRC) risk is predominantly driven by environmental factors, in particular diet. A high intake of dietary fat has been implicated as a risk factor inducing the formation of pre-neoplastic lesions (e.g., adenomatous polyps) and/or exacerbating colonic tumorigenesis. Recent data attributed the tumor-promoting activity of high-fat diets to their effects on gut microbiota composition and metabolism, in particular with regard to bile acids. Bile acids are synthesized in the liver in response to dietary fat and facilitate lipid absorption in the small intestine. The majority of bile acids is re-absorbed during small intestinal transit and subjected to enterohepatic circulation. Bile acids entering the colon undergo complex biotransformation performed by gut bacteria, resulting in secondary bile acids that show tumor-promoting activity. Excessive dietary fat leads to high levels of secondary bile acids in feces and primes the gut microbiota to bile acid metabolism. This promotes an altered overall bile acid pool, which activates or restricts intestinal and hepatic cross-signaling of the bile acid receptor, farnesoid X receptor (FXR). Recent studies provided evidence that FXR is a main regulator of bile acid-mediated effects on intestinal tumorigenesis integrating dietary, microbial and genetic risk factors for CRC. Selective FXR agonist or antagonist activity by specific bile acids depends on additional factors (e.g., bile acid concentration, composition of bile acid pool, genetic instability of cells) and, thus, may differ in healthy and tumorigenic conditions in the intestine. In conclusion, fat-mediated alterations of the gut microbiota link bile acid metabolism to CRC risk and colonic tumorigenesis, exemplifying how gut microbial co-metabolism affects colon health.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bile acids; Colorectal cancer; Dietary fat; Farnesoid X receptor; Gut microbiota

Mesh:

Substances:

Year:  2020        PMID: 33069873     DOI: 10.1016/j.semcancer.2020.10.003

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  24 in total

1.  Pleiotropic roles of FXR in liver and colorectal cancers.

Authors:  Xiongfei Huang; Mingjie Fan; Wendong Huang
Journal:  Mol Cell Endocrinol       Date:  2022-01-04       Impact factor: 4.102

2.  Fecal microbiome and bile acid metabolome in adult short bowel syndrome.

Authors:  Harold J Boutte; Jacqueline Chen; Todd N Wylie; Kristine M Wylie; Yan Xie; Mackenzie Geisman; Anirudh Prabu; Vered Gazit; Phillip I Tarr; Marc S Levin; Brad W Warner; Nicholas O Davidson; Deborah C Rubin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-11-24       Impact factor: 4.052

3.  Features of colorectal cancer in China stratified by anatomic sites: A hospital-based study conducted in university-affiliated hospitals from 2014 to 2018.

Authors:  Ruize Qu; Yanpeng Ma; Liyuan Tao; Xiaoyuan Bao; Xin Zhou; Bingyan Wang; Fei Li; Siyi Lu; Lin Tuo; Siyan Zhan; Zhipeng Zhang; Wei Fu
Journal:  Chin J Cancer Res       Date:  2021-08-31       Impact factor: 5.087

4.  Long Non-Coding RNA LINC01569 Promotes Proliferation and Metastasis in Colorectal Cancer by miR-381-3p/RAP2A Axis.

Authors:  Guang-Yao Ye; Zi-Zhen Zhang; Chun-Chao Zhu; Zhi-Jie Cong; Zhe Cui; Lu Chen; Gang Zhao
Journal:  Front Oncol       Date:  2021-08-06       Impact factor: 6.244

5.  Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.

Authors:  Akira Ooki; Satoshi Morita; Akihito Tsuji; Shigeyoshi Iwamoto; Hiroki Hara; Hiroaki Tanioka; Hironaga Satake; Masato Kataoka; Masahito Kotaka; Yoshinori Kagawa; Masato Nakamura; Tatsushi Shingai; Masashi Ishikawa; Yasuhiro Miyake; Takeshi Suto; Yojiro Hashiguchi; Taichi Yabuno; Masahiko Ando; Junichi Sakamoto; Kensei Yamaguchi
Journal:  BMC Cancer       Date:  2022-06-28       Impact factor: 4.638

6.  Combination of Geriatric Nutritional Risk Index and Carcinoembryonic Antigen to Predict the Survival of Patients With Colorectal Cancer.

Authors:  Hailun Xie; Lishuang Wei; Guanghui Yuan; Mingxiang Liu; Yanren Liang; Shunhui Gao; Qiwen Wang; Xin Lin; Shuangyi Tang; Jialiang Gan
Journal:  Front Nutr       Date:  2022-06-30

Review 7.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 8.  Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention.

Authors:  Jadwiga Maniewska; Dagmara Jeżewska
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

9.  Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation.

Authors:  Peijie Wu; Ling Qiao; Han Yu; Hui Ming; Chao Liu; Wenjun Wu; Baixue Li
Journal:  Front Cell Dev Biol       Date:  2021-12-02

10.  Dietary Fat Intake and KRAS Mutations in Colorectal Cancer in a Moroccan Population.

Authors:  Achraf El Asri; Karim Ouldim; Laila Bouguenouch; Mohammed Sekal; Fatima Zahra Moufid; Ellen Kampman; Inge Huybrechts; Marc J Gunter; Sanae Abbaoui; Kaoutar Znati; Mehdi Karkouri; Khaoula El Kinany; Zineb Hatime; Meimouna Mint Sidi Deoula; Laila Chbani; Btissame Zarrouq; Karima El Rhazi
Journal:  Nutrients       Date:  2022-01-13       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.